News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Data From Intercept Pharmaceuticals (ICPT)'s Pivotal Phase 3 POISE Trial Of Its FXR Agonist Obeticholic Acid To Treat Primary Biliary Cirrhosis And Other Key Obeticholic Acid Data To Be Presented At EASL 2014



4/7/2014 8:53:16 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, April 4, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, today announced presentations of key data at the International Liver Congress 2014, the 49th Annual Meeting of the European Association for the Study of the Liver (EASL), being held in London, UK, at the ExCel Centre from April 9-13, 2014. Intercept will be exhibiting at booth #715 throughout the Congress.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   
Cirrhosis

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES